Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Not applicable

Blood Purification for the Treatment of Pathogen Associated Shock

NCT05011656 · tracked via the Priya Life Science USA tracker
Sponsor
ExThera Medical Corporation
Phase
Not applicable
Started
2024-04-19
Last updated
2026-04-14

Condition(s) studied

Septic Shock

Investigational drug(s) / intervention(s)

Seraph-100 + State of the Art CareState of the Art Care

Seraph-100 + State of the Art Care: Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) manufactured by ExThera Medical Corporation in Martinez, CA. The Seraph 100 filter has been designed and manufactured to reduce residual risks as much as possible to ensure safe usage. Literature search results concluded that heparin-coated medical devices are safe and decrease platelet adhesion without affecting the adsorption of major adhesive proteins. The efficacy, safety, and risk-benefit data of the studies suggest that Seraph 100 is also safe and potentially beneficial by reducing the rate of thrombosis, without its use entailing a risk for patients. The achieved results from the above-mentioned testing and studies support the performance and safety of Seraph 100 consistent with the intended use. ExThera Medical concludes that the known and potential benefits of Seraph 100, when used to treat patients with pathogen associated shock, outweigh the known and potential risks when used according to the intended use.

State of the Art Care: "State of the Art care"is defined as the treatment algorithms outlined in the Surviving Sepsis Campaign for the treatment of septic shock, available at https://www.sccm.org/SurvivingSepsisCampaign/Home

Study summary

This study is a multi-center, randomized controlled feasibility trial to evaluate the initial safety and efficacy of a novel extracorporeal blood purification (EBP) therapy in critically ill patients with pathogen associated shock across 15 U.S. sites. Adults (18 years old and older) admitted to the ICU with all of the following:

• Pathogen associated shock defined as:

* The need for vasopressors to maintain mean arterial pressure (MAP) ≥ 65 mmHg despite adequate fluid resuscitation
* Presence of a pathogen detected in the bloodstream within 72 hours of screening using commercially available in-vitro diagnostic testing

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Admitted to an ICU with pathogen associated shock defined as: * The need for vasopressors to maintain mean arterial pressure (MAP) ≥ 65 mmHg despite adequate fluid resuscitation, AND * Presence of a pathogen detected in the bloodstream within 72 hours of screening using commercially available in-vitro diagnostic testing 2. Male or non-pregnant female adult 3. At least 18 years of age at time of enrollment Exclusion Criteria: 1. Pregnant or breast feeding 2. Anticipated transfer to another hospital (that is not a study site) within 72 hours for any reason 3. Not anticipated to survive more than 24 hours 4. Known allergy to heparin sodium 5. Patients who cannot tolerate placement of double-lumen catheter 6. High risk of bleeding (platelet count \<50mm3 or International Normalized Ratio (INR) \>2) unless adequate line for treatment already placed (e.g. ECMO or RRT/CRRT) 7. Inability to tolerate extracorporeal therapy (defined as MAP\<65 despite fluids and vasopressors) 8. Advanced cancer (defined as stage IV) with life expectancy of less than 30 days 9. Unable to obtain informed consent from either patient or legally authorized representative (LAR) 10. Hypotension and volume depletion due to etiologies other than sepsis. 11. Neutropenia with an absolute neutrophil count \<500mm3 12. Patients must be treated with one of the antimicrobial agents listed in the Antimicrobial Management Guideline (Table 19). Patients who require treatment with an antimicrobial outside of this list while still receiving treatment with the investigational device must be excluded from the study. 13. If a patient enters the study and later requires a change in the antimicrobial agent used to one which is not listed in the Antimicrobial Management Guideline while still receiving treatment with the investigational device, that patient must be removed from this trial. Clinical data for any patient removed from the trial for this reason will continue to be collected for safety evaluation". 14. Patient is a prisoner or member of a different vulnerable population that should not be included in the study per the investigator or IRB/ethics committee. 15. Advanced directive for "Do Not Resuscitate".

Primary outcome measure(s)

  • Efficacy - ICU-free days in the first 28 days — First 28 days
    Alive and not in the ICU (for at least a fulle 24 hours) in the first 28 days from the time of randomization
  • Safety - Adverse Events — Discharge from hospital
    SAEs and \>/= grade 3 AEs per CTCAE v5 evaluated from enrollment until the end of hospitalization

Trial sites (9)

FacilityCityRegionStatus
George Washington University Washington D.C. District of Columbia
Southeast Georgia Health System, Inc. Brunswick Georgia
University of Michigan Ann Arbor Michigan
Mayo Clinic Rochester Minnesota
Good Samaritan Hospital Corvallis Oregon
Trinity Health Mid Atlantic-SMMC Langhorne Pennsylvania
University of Texas Southwestern Medical Center Dallas Texas
Methodist Hospital San Antonio Texas
University of Texas Health Science Center at San Antonio (UT Health San Antonio) San Antonio Texas
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05011656 on ClinicalTrials.gov ↗ ← All trials in the USA